<DOC>
	<DOCNO>NCT01254188</DOCNO>
	<brief_summary>This study investigate safety efficacy nilotinib newly diagnose chronic myeloid leukemia patient chronic phase</brief_summary>
	<brief_title>Safety Efficacy Nilotinib Newly Diagnosed Chronic Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients chronic myeloid leukemia chronic phase diagnose within 6 month study entry Treatment tyrosine kinase inhibitor antileukemic agent treatment ( include HSCT ) longer 2 week , exception hydroxyurea and/or anagrelide Uncontrolled congestive heart failure hypertension Myocardial infarction unstable angina pectoris within past 12 month Known T315I mutation QTcF &gt; 450 msec Significant arrhythmias Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic myeloid leukemia ,</keyword>
	<keyword>CML ,</keyword>
	<keyword>nilotinib ,</keyword>
	<keyword>myelogenous ,</keyword>
	<keyword>Philadelphia chromosome</keyword>
</DOC>